Anticancer Activity of Natural Compounds from Plant and Marine Environment
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pro-Oxidizing Metabolic Weapons ☆ ⁎ Etelvino J.H
Comparative Biochemistry and Physiology, Part C 146 (2007) 88–110 www.elsevier.com/locate/cbpc Review The dual face of endogenous α-aminoketones: Pro-oxidizing metabolic weapons ☆ ⁎ Etelvino J.H. Bechara a, , Fernando Dutra b, Vanessa E.S. Cardoso a, Adriano Sartori a, Kelly P.K. Olympio c, Carlos A.A. Penatti d, Avishek Adhikari e, Nilson A. Assunção a a Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes 748, 05508-900, São Paulo, SP, Brazil b Centro de Ciências Biológicas e da Saúde, Universidade Cruzeiro do Sul, São Paulo, SP, Brazil c Faculdade de Saúde Pública, Universidade de São Paulo, São Paulo, SP, Brazil d Department of Physiology, Dartmouth Medical School, Hanover, NH, USA e Department of Biological Sciences, Columbia University, New York, NY, USA Received 31 January 2006; received in revised form 26 June 2006; accepted 6 July 2006 Available online 14 July 2006 Abstract Amino metabolites with potential prooxidant properties, particularly α-aminocarbonyls, are the focus of this review. Among them we emphasize 5-aminolevulinic acid (a heme precursor formed from succinyl–CoA and glycine), aminoacetone (a threonine and glycine metabolite), and hexosamines and hexosimines, formed by Schiff condensation of hexoses with basic amino acid residues of proteins. All these metabolites were shown, in vitro, to undergo enolization and subsequent aerobic oxidation, yielding oxyradicals and highly cyto- and genotoxic α-oxoaldehydes. Their metabolic roles in health and disease are examined here and compared in humans and experimental animals, including rats, quail, and octopus. In the past two decades, we have concentrated on two endogenous α-aminoketones: (i) 5-aminolevulinic acid (ALA), accumulated in acquired (e.g., lead poisoning) and inborn (e.g., intermittent acute porphyria) porphyric disorders, and (ii) aminoacetone (AA), putatively overproduced in diabetes mellitus and cri-du-chat syndrome. -
Multiple Low-Dose Streptozotocin-Induced Diabetes in the Mouse
Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. R C McEvoy, … , S Sandler, C Hellerström J Clin Invest. 1984;74(3):715-722. https://doi.org/10.1172/JCI111487. Research Article Mice were examined for the presence of splenocytes specifically cytotoxic for a rat insulinoma cell line (RIN) during the induction of diabetes by streptozotocin (SZ) in multiple low doses (Multi-Strep). Cytotoxicity was quantitated by the release of 51Cr from damaged cells. A low but statistically significant level of cytolysis (5%) by splenocytes was first detectable on day 8 after the first dose of SZ. The cytotoxicity reached a maximum of approximately 9% on day 10 and slowly decreased thereafter, becoming undetectable 42 d after SZ was first given. The time course of the in vitro cytotoxic response correlated with the degree of insulitis demonstrable in the pancreata of the Multi-Strep mice. The degree of cytotoxicity after Multi-Strep was related to the number of effector splenocytes to which the target RIN cells were exposed and was comparable to that detectable after immunization by intraperitoneal injection of RIN cells in normal mice. The cytotoxicity was specific for insulin-producing cells; syngeneic, allogeneic, and xenogeneic lymphocytes and lymphoblasts, 3T3 cells, and a human keratinocyte cell line were not specifically lysed by the splenocytes of the Multi- Strep mice. This phenomenon was limited to the Multi-Strep mice. Splenocytes from mice made diabetic by a single, high dose of SZ exhibited a very low level of cytotoxicity against the RIN cells. -
81196615.Pdf
Biochimie 94 (2012) 374e383 Contents lists available at ScienceDirect Biochimie journal homepage: www.elsevier.com/locate/biochi Research paper Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats Roberta Schmatz a,*, Luciane Belmonte Perreira a, Naiara Stefanello a, Cinthia Mazzanti a, Roselia Spanevello a,c, Jessié Gutierres a, Margarete Bagatini b, Caroline Curry Martins a, Fátima Husein Abdalla a, Jonas Daci da Silva Serres a, Daniela Zanini a, Juliano Marchi Vieira a, Andréia Machado Cardoso a, Maria Rosa Schetinger a, Vera Maria Morsch a,* a Programa de Pós Graduação em Bioquímica Toxicológica, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Campus Universitário, Camobi, 97105-900 Santa Maria, RS, Brazil b Colegiado do curso de Enfermagem, Universidade Federal da Fronteira Sul, Campus Chapecó, Chapecó, SC, Brazil c Universidade Federal de Pelotas, Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Setor de Bioquímica, Campus Universitário Capão do Leão 96010-900 Pelotas, RS, Brazil article info abstract Article history: The present study investigated the effects of resveratrol (RV), a polyphenol with potent antioxidant Received 24 April 2011 properties, on oxidative stress parameters in liver and kidney, as well as on serum biochemical Accepted 8 August 2011 parameters of streptozotocin (STZ)-induced diabetic rats. Animals were divided into six groups (n ¼ 8): Available online 16 August 2011 control/saline; control/RV 10 mg/kg; control/RV 20 mg/kg; diabetic/saline; diabetic/RV10 mg/kg; dia- betic/RV 20 mg/kg. After 30 days of treatment with resveratrol the animals were sacrificed and the liver, Keywords: kidney and serum were used for experimental determinations. -
Metals and Metal Compounds in Cancer Treatment
ANTICANCER RESEARCH 24: 1529-1544 (2004) Review Metals and Metal Compounds in Cancer Treatment BERNARD DESOIZE Laboratoire de Biochimie et de Biologie Moléculaire, EA 3306, IFR 53, Faculté de Pharmacie, 51 rue Cognacq-Jay, 51096 Reims cedex, France Abstract. Metals and metal compounds have been used in The importance of metal compounds in medicine is medicine for several thousands of years. In this review we undisputed, as can be judged by the use of compounds of summarized the anti-cancer activities of the ten most active antimony (anti-protozoal), bismuth (anti-ulcer), gold (anti- metals: arsenic, antimony, bismuth, gold, vanadium, iron, arthritic), iron (anti-malarial), silver (anti-microbial) and rhodium, titanium, gallium and platinum. The first reviewed platinum (anti-cancer) in the treatment of various diseases. metal, arsenic, presents the anomaly of displaying anti-cancer In terms of anti-tumour activity, a wide range of compounds and oncogenic properties simultaneously. Some antimony of both transition metals and main group elements have derivatives, such as Sb2O3, salt (tartrate) and organic been investigated for efficacy (1). The earliest reports on the compounds, show interesting results. Bismuth directly affects therapeutic use of metals or metal-containing compounds in Helicobacter pylori and gastric lymphoma; the effects of cancer and leukemia date from the sixteenth century. bismuth complexes of 6-mercaptopurine are promising. Superoxide dismutase inhibition leads to selective killing Gold(I) and (III) compounds show anti-tumour activities, of cancer cells in vitro and in vivo (2,3). As a consequence, although toxicity remains high. Research into the potential use reactive oxygen species (ROS) may not only be involved in of gold derivatives is still ongoing. -
Phase III Trial of Chemotherapy Using 5-Fluorouracil and Streptozotocin
Endocrine-Related Cancer (2009) 16 1351–1361 Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon a for advanced carcinoid tumors: FNCLCC–FFCD 9710 Laetitia Dahan1*, Frank Bonnetain2*, Philippe Rougier 3, Jean-Luc Raoul 4, Eric Gamelin5, Pierre-Luc Etienne6, Guillaume Cadiot 7, Emmanuel Mitry4, Denis Smith8, Fre´de´rique Cvitkovic9, Bruno Coudert 10, Floriane Ricard1, Laurent Bedenne1, Jean-Franc¸ois Seitz1 for the Fe´de´ration Francophone de Cance´rologie Digestive (FFCD) and the Digestive Tumors Group of the Fe´de´ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC) 1Assistance Publique, Hoˆpitaux de Marseille, Hoˆpital Timone, Universite´ de la Me´diterrane´e, CHU Timone, 264 rue Saint Pierre, 13385 Marseille Cedex 5, France 2FFCD, Dijon, France 3AP-HP, Hoˆpital Ambroise Pare´, Boulogne, France 4Centre Euge`ne Marquis, Rennes, France 5Centre Paul Papin, Angers, France 6Clinique Armoricaine, Saint Brieuc, France 7Hopital Robert Debre´, Reims, France 8CHU Haut Leveque, Pessac, France 9Centre Rene´ Huguenin, Saint Cloud, France 10Centre Franc¸ois Leclerc, Dijon, France (Correspondence should be addressed to L Dahan; Email: [email protected]) *(L Dahan and F Bonnetain contributed equally to this work) Abstract The aim of this randomized multicenter phase III trial was to compare chemotherapy and interferon (IFN) in patients with metastatic carcinoid tumors. Patients with documented progressive, unresectable, metastatic carcinoid tumors were randomized between 5-fluorouracil plus streptozotocin (day 1–5) and recombinant IFN-a-2a (3 MU!3 per week). Primary endpoint was progression-free survival (PFS). From February 1998 to June 2004, 64 patients were included. -
Eldisine * (Vindesine Sulphate)
PACKAGE LEAFLET: INFORMATION FOR THE USER 2. WHAT YOU NEED TO KNOW BEFORE YOU USE ELDISINE your bone marrow. These cells divide quickly to make new blood Do not use Eldisine if you: cells. Your doctor or nurse will take samples of your blood when Eldisine * • are allergic to vindesine sulphate or any of the other ingredients you are treated with Eldisine. The hospital’s laboratory will then (Vindesine Sulphate) in Eldisine (see section 6 – Contents of the pack and other count the numbers of different types of blood cells (platelets, white information) cells and red cells). Your doctor may decide to change the dose or Read all of this leaflet carefully before you start taking this • suffer from any disease affecting the nerves or muscles (such as put off treating you if your blood cell counts are too low. Your blood medicine. Charcot-Marie-Tooth syndrome) cell counts soon improve as the bone marrow makes new cells. - Keep this leaflet. You may need to read it again. • have a bacterial infection. A lot of injections (more than one a week) may cause more side- - If you have any further questions, ask your doctor or pharmacist. Warnings and precautions effects. - This medicine has been prescribed for you. Do not pass it on to Talk to your doctor or pharmacist before using Eldisine if you: Eldisine works by sticking to certain molecules in dividing cells to others. It may harm them, even if their signs of illness are the • are having radiotherapy in the liver area stop the cells dividing. It also sticks to the same sort of molecule in same as yours. -
Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of Neurooncology Magazine 2012; 2 (1) 25-36
Volume 2 (2012) // Issue 1 // e-ISSN 2224-3453 Neurology · Neurosurgery · Medical Oncology · Radiotherapy · Paediatric Neuro- oncology · Neuropathology · Neuroradiology · Neuroimaging · Nursing · Patient Issues Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of NeuroOncology Magazine 2012; 2 (1) 25-36 Homepage: www.kup.at/ journals/eano/index.html OnlineOnline DatabaseDatabase FeaturingFeaturing Author,Author, KeyKey WordWord andand Full-TextFull-Text SearchSearch THE EUROPEAN ASSOCIATION OF NEUROONCOLOGY Member of the Chemotherapy and Polyneuropathies Chemotherapy and Polyneuropathies Wolfgang Grisold1, Stefan Oberndorfer2, Anthony J Windebank3 Abstract: Peripheral neuropathies induced by taxanes) immediate effects can appear, caused to be caused by chemotherapy or other mecha- chemotherapy (CIPN) are an increasingly frequent by different mechanisms. The substances that nisms, whether treatment needs to be modified problem. Contrary to haematologic side effects, most frequently cause CIPN are vinca alkaloids, or stopped due to CIPN, and what symptomatic which can be treated with haematopoetic taxanes, platin derivates, bortezomib, and tha- treatment should be recommended. growth factors, neither prophylaxis nor specific lidomide. Little is known about synergistic neu- Possible new approaches for the management treatment is available, and only symptomatic rotoxicity caused by previously given chemo- of CIPN could be genetic susceptibility, as there treatment can be offered. therapies, or concomitant chemotherapies. The are some promising advances with vinca alka- CIPN are predominantly sensory, duration-of- role of pre-existent neuropathies on the develop- loids and taxanes. Eur Assoc Neurooncol Mag treatment-dependent neuropathies, which de- ment of a CIPN is generally assumed, but not 2012; 2 (1): 25–36. velop after a typical cumulative dose. Rarely mo- clear. -
Fungal Endophytes As Efficient Sources of Plant-Derived Bioactive
microorganisms Review Fungal Endophytes as Efficient Sources of Plant-Derived Bioactive Compounds and Their Prospective Applications in Natural Product Drug Discovery: Insights, Avenues, and Challenges Archana Singh 1,2, Dheeraj K. Singh 3,* , Ravindra N. Kharwar 2,* , James F. White 4,* and Surendra K. Gond 1,* 1 Department of Botany, MMV, Banaras Hindu University, Varanasi 221005, India; [email protected] 2 Department of Botany, Institute of Science, Banaras Hindu University, Varanasi 221005, India 3 Department of Botany, Harish Chandra Post Graduate College, Varanasi 221001, India 4 Department of Plant Biology, Rutgers University, New Brunswick, NJ 08901, USA * Correspondence: [email protected] (D.K.S.); [email protected] (R.N.K.); [email protected] (J.F.W.); [email protected] (S.K.G.) Abstract: Fungal endophytes are well-established sources of biologically active natural compounds with many producing pharmacologically valuable specific plant-derived products. This review details typical plant-derived medicinal compounds of several classes, including alkaloids, coumarins, flavonoids, glycosides, lignans, phenylpropanoids, quinones, saponins, terpenoids, and xanthones that are produced by endophytic fungi. This review covers the studies carried out since the first report of taxol biosynthesis by endophytic Taxomyces andreanae in 1993 up to mid-2020. The article also highlights the prospects of endophyte-dependent biosynthesis of such plant-derived pharma- cologically active compounds and the bottlenecks in the commercialization of this novel approach Citation: Singh, A.; Singh, D.K.; Kharwar, R.N.; White, J.F.; Gond, S.K. in the area of drug discovery. After recent updates in the field of ‘omics’ and ‘one strain many Fungal Endophytes as Efficient compounds’ (OSMAC) approach, fungal endophytes have emerged as strong unconventional source Sources of Plant-Derived Bioactive of such prized products. -
Protective Effect of Curcumin Against Irinotecan‑Induced Intestinal
1376 INTERNATIONAL JOURNAL OF ONCOLOGY 54: 1376-1386, 2019 Protective effect of curcumin against irinotecan‑induced intestinal mucosal injury via attenuation of NF‑κB activation, oxidative stress and endoplasmic reticulum stress MANZHAO OUYANG1*, ZHENTAO LUO1*, WEIJIE ZHANG1*, DAJIAN ZHU2, YAN LU1, JINHAO WU1 and XUEQING YAO3,4 1Department of Gastrointestinal Surgery, Shunde Hospital, Southern Medical University, Shunde, Foshan, Guangdong 528308; 2Department of Gastrointestinal Surgery, Shunde Women and Children's Health Care Hospital of Shunde, Foshan, Guangdong 528300; 3Department of General Surgery, Guangdong General Hospital and Guangdong Academy of Medical Sciences; 4The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510080, P.R. China Received March 28, 2018; Accepted December 6, 2018 DOI: 10.3892/ijo.2019.4714 Abstract. Irinotecan (CPT-11) is a DNA topoisomerase I analysis. The results revealed that in vivo, curcumin effectively inhibitor which is widely used in clinical chemotherapy, attenuated the symptoms of diarrhea and abnormal intestinal particularly for colorectal cancer treatment. However, late-onset mucosa structure induced by CPT-11 in nude mice. Treatment diarrhea is one of the severe side-effects of this drug and this with curcumin also increased the expression of P4HB and restricts its clinical application. The present study aimed to PRDX4 in the tissue of the small intestine. In vitro, curcumin, investigate the protective effects of curcumin treatment on exhibited little cytotoxicity when used at concentrations CPT-11-induced intestinal mucosal injury both in vitro and <2.5 µg/ml for 24 h in IEC-6 cells. At this concentration, in vivo and to elucidate the related mechanisms involved in curcumin also improved cell morphology, inhibited apoptosis, these effects. -
Vinorelbine Inj. USP
VINORELBINE INJECTION USP survival between the 2 treatment groups. Survival (Figure 1) for patients receiving Vinorelbine Injection USP pIus cisplatin was Patients treated with Vinorelbine Injection USP should be frequently monitored for myelosuppression both during and after significantly better compared to the-patients who received single-agent cisplatin. The results of this trial are summarized in Table 1. therapy. Granulocytopenia is dose-limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count PRESCRIBING INFORMATION Vinorelbine Injection USP plus Cisplatin versus Vindesine plus Cisplatin versus Single-Agent Vinorelbine Injection USP: In a recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed and results large European clinical trial, 612 patients with Stage III or IV NSCLC, no prior chemotherapy, and WHO Performance Status of 0, 1, reviewed prior to administering each dose of Vinorelbine Injection USP. Vinorelbine Injection USP should not be administered to WARNING: Vinorelbine Injection USP should be administered under the supervision of a physician experienced in the use of or 2 were randomized to treatment with single-agent Vinorelbine Injection USP (30 mg/m2/week), Vinorelbine Injection USP (30 patients with granulocyte counts <1,000 cells/mm3. Patients developing severe granulocytopenia should be monitored carefully for cancer chemotherapeutic agents. This product is for intravenous (IV) use only. Intrathecal administration of other vinca alkaloids mg/m2/week) plus cisplatin (120 mg/m2 days 1 and 29, then every 6 weeks), and vindesine (3 mg/m2/week for 7 weeks, then every evidence of infection and/or fever. See DOSAGE AND ADMINISTRATION for recommended dose adjustments for granulocytopenia. -
Combinatorial Treatment with Mtor Inhibitors and Streptozotocin Leads
Published OnlineFirst October 19, 2017; DOI: 10.1158/1535-7163.MCT-17-0325 Small Molecule Therapeutics Molecular Cancer Therapeutics Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells Julien Bollard1,2,Celine Patte1,2, Patrick Massoma2, Isabelle Goddard2, Nicolas Gadot3, Noura Benslama2,Valerie Hervieu1,2,4,5, Carole Ferraro-Peyret2,4,5, Martine Cordier-Bussat2, Jean-Yves Scoazec6,7, Colette Roche1,2, Thomas Walter1,2,5,8, and Cecile Vercherat1,2 Abstract Streptozotocin-based chemotherapy is the first-line chemo- mTORC1 and mTORC2). Effects on cell viability and apoptosis therapy recommended for advanced pancreatic neuroendocrine were assessed in insulinoma cell lines INS-1E (rat) and MIN6 tumors (pNETs), whereas targeted therapies, including mTOR (mouse) in vitro and were confirmed in vivo by using a mouse inhibitors, are available in second-line treatment. Unfortunate- model of hepatic tumor dissemination after intrasplenic xeno- ly, objective response rates to both treatments are limited. graft. In vitro, all four combinations display synergistic effects. Because mTOR pathway activation, commonly observed in These combinations lead to heterogeneous mTOR pathway pNETs, has been reported as one of the major mechanisms inhibition, in agreement with their respective target, and accounting for chemoresistance, we investigated the potential increased apoptosis. In vivo, tumor growth in the liver was benefit of mTOR inhibition combined with streptozotocin significantly inhibited by combining streptozotocin with ever- treatment in a subset of pNETs, namely insulinomas. To eval- olimus (P ¼ 0.0014), BKM120 (P ¼ 0.0092), or BEZ235 (P ¼ uate the potential of mTOR inhibition in combination with 0.008) as compared to each agent alone. -
DRUG NAME: Vinorelbine
Vinorelbine DRUG NAME: Vinorelbine SYNONYM(S): Vinorelbine tartrate, VRL, VNL, NVB COMMON TRADE NAME(S): NAVELBINE® CLASSIFICATION: Mitotic inhibitor Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Vinorelbine is a semisynthetic vinca alkaloid derived from vinblastine. Vinca alkaloids such as vincristine and vinblastine are originally derived from periwinkle leaves (vinca rosea).1 Vinorelbine inhibits cell growth by binding to the tubulin of the mitotic microtubules.2 Like other mitotic inhibitors, vinorelbine also promotes apoptosis in cancer cells.1 In vitro vinorelbine shows both multidrug and non-multidrug resistance.2 Microtubules are present in mitotic spindles, neuronal axons, and other cells. Inhibition of mitotic microtubules appears to correlate with antitumour activity, while inhibition of axonal microtubules seems to correlate with neurotoxicity. Compared to vincristine and vinblastine, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.3 Vinorelbine is a radiation-sensitizing agent.4 It is cell cycle phase-specific (M phase).2 PHARMACOKINETICS: Interpatient variability moderate to large interpatient variability5,6 Distribution Widely distributed in the body, mostly in spleen, liver, kidneys, lungs, thymus; moderately in heart, muscles; minimally in fat, brain, bone marrow.3 High levels found in both normal and malignant lung tissue, with slow diffusion out of tumour tissue.1 cross